Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has earned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $3.33.

Separately, StockNews.com initiated coverage on shares of Syros Pharmaceuticals in a research report on Friday. They set a “sell” rating on the stock.

Syros Pharmaceuticals Stock Performance

Shares of Syros Pharmaceuticals stock opened at $0.06 on Tuesday. The firm’s 50-day simple moving average is $0.16 and its 200-day simple moving average is $0.85. Syros Pharmaceuticals has a twelve month low of $0.06 and a twelve month high of $6.93. The firm has a market cap of $1.65 million, a P/E ratio of -0.02 and a beta of 1.31.

Hedge Funds Weigh In On Syros Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new position in Syros Pharmaceuticals in the third quarter valued at about $34,000. Two Sigma Securities LLC acquired a new position in Syros Pharmaceuticals in the fourth quarter valued at about $25,000. Finally, Exome Asset Management LLC boosted its position in Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after buying an additional 139,400 shares in the last quarter. 91.47% of the stock is currently owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.